Stay updated on PBCAR269A Dose-escalation Clinical Trial
Sign up to get notified when there's something new on the PBCAR269A Dose-escalation Clinical Trial page.

Latest updates to the PBCAR269A Dose-escalation Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. The change reflects an internal site revision recorded in the page history.SummaryDifference0.1%

- Check32 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2 from the version history.SummaryDifference0.1%

- Check60 days agoChange DetectedA new Revision: v3.4.2 entry has been added to the study record history, and the prior banner notice about government funding (Revision: v3.4.1) has been removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check67 days agoChange DetectedA site-wide notice about government funding is added and the record shows a new revision v3.4.1, replacing the previous v3.4.0.SummaryDifference0.8%

- Check74 days agoChange DetectedUI updates add a 'Show glossary' control and color-coding for changes (green for additions and red for deletions) on the study history page, and the revision tag has been updated to v3.4.0 with minor wording adjustments to No FEAR Act data; no substantive study data changes were made. To avoid alerting on small changes, set an alert condition below.SummaryDifference1%

- Check82 days agoChange DetectedRecord history shows a new revision entry (v3.3.4) added and the prior revision (v3.3.3) removed; this reflects versioning metadata rather than changes to study data or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to PBCAR269A Dose-escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PBCAR269A Dose-escalation Clinical Trial page.